Could poop pills help fight breast cancer? new trial aims to find out
NCT ID NCT07292142
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether fecal microbiota transplants (FMT) from healthy donors can safely be added to standard chemotherapy and immunotherapy for triple-negative breast cancer. About 125 patients will take part, first in an observation phase and then in a treatment phase. The goal is to see if changing the gut bacteria can help more tumors respond fully to treatment before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fecal microbiota transplantation (FMT) from healthy donors
What this could lead to
If it works, this could point toward a way to make standard breast cancer treatment more effective for patients whose tumors don't fully respond.
What could go wrong
This is a very early, small pilot study (Phase 1/2) focused on safety and feasibility, not yet on effectiveness. The approach may not improve outcomes and could cause side effects from the transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
London Health Sciences Center
London, Ontario, Canada
Contact Email: •••••@•••••
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Contact Email: •••••@•••••